n,n-dimethylarginine has been researched along with rosiglitazone in 3 studies
| Studies (n,n-dimethylarginine) | Trials (n,n-dimethylarginine) | Recent Studies (post-2010) (n,n-dimethylarginine) | Studies (rosiglitazone) | Trials (rosiglitazone) | Recent Studies (post-2010) (rosiglitazone) |
|---|---|---|---|---|---|
| 2,216 | 228 | 1,221 | 4,749 | 556 | 1,818 |
| Protein | Taxonomy | n,n-dimethylarginine (IC50) | rosiglitazone (IC50) |
|---|---|---|---|
| CDGSH iron-sulfur domain-containing protein 1 | Rattus norvegicus (Norway rat) | 1.1 | |
| Bile salt export pump | Homo sapiens (human) | 4.5853 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 4.069 | |
| Peroxisome proliferator-activated receptor alpha | Mus musculus (house mouse) | 0.08 | |
| Thromboxane-A synthase | Homo sapiens (human) | 3.56 | |
| Amine oxidase [flavin-containing] B | Homo sapiens (human) | 0.832 | |
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | 0.2481 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.038 | |
| ATP-binding cassette sub-family C member 8 | Homo sapiens (human) | 0.048 | |
| ATP-sensitive inward rectifier potassium channel 11 | Homo sapiens (human) | 0.048 | |
| Sodium/bile acid cotransporter | Homo sapiens (human) | 5.1 | |
| CDGSH iron-sulfur domain-containing protein 2 | Homo sapiens (human) | 2.29 | |
| CDGSH iron-sulfur domain-containing protein 1 | Homo sapiens (human) | 0.731 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abbasi, F; Chu, JW; Cooke, JP; Lamendola, C; McLaughlin, TL; Reaven, GM; Stühlinger, MC; Tsao, PS | 1 |
| Bank, AJ; Gonzalez-Campoy, JM; Kaiser, DR; Kelly, AS; Thelen, AM | 1 |
| de Vries, TP; Ellger, B; Girbes, AR; Richir, MC; Siroen, MP; Spreeuwenberg, M; Teerlink, T; van den Berghe, G; van der Hoven, B; van Leeuwen, PA; Visser, M; Wilhelm, AJ | 1 |
2 trial(s) available for n,n-dimethylarginine and rosiglitazone
| Article | Year |
|---|---|
Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Arginine; Biomarkers; Blood Glucose; Blood Pressure; Brachial Artery; C-Reactive Protein; Carotid Arteries; Diabetes Mellitus; Double-Blind Method; Drug Therapy, Combination; Elasticity; Endothelium, Vascular; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inflammation; Insulin; Male; Metformin; Middle Aged; Oxidative Stress; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Vasodilation | 2007 |
The effect of rosiglitazone on asymmetric dimethylarginine (ADMA) in critically ill patients.
Topics: Aged; Arginine; Critical Illness; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pilot Projects; Rosiglitazone; Thiazolidinediones | 2009 |
1 other study(ies) available for n,n-dimethylarginine and rosiglitazone
| Article | Year |
|---|---|
Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor.
Topics: Adult; Aged; Arginine; Cardiovascular Diseases; Cross-Sectional Studies; Enzyme Inhibitors; Female; Humans; Hypertension; Hypoglycemic Agents; Lipoproteins; Male; Metabolic Diseases; Metabolic Syndrome; Middle Aged; Nitric Oxide Synthase; Regression Analysis; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; Vasodilator Agents | 2002 |